Skip to main content
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. — Investor Relations & Filings

Ticker · SABS ISIN · US0891152086 US Manufacturing
Open in API
Filings indexed 398 across all filing types
Latest filing 2024-02-02 Board/Management Inform…
Country US United States of America
Listing US SABS

About SAB Biotherapeutics, Inc.

https://www.sab.bio/

SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a novel class of immunotherapies. The company's proprietary platform produces targeted, high-potency, fully human polyclonal antibodies without the need for human donors. This technology utilizes transgenic cattle to generate natural human antibodies in response to specific disease targets. The company's lead product candidate, SAB-142, is a disease-modifying immunotherapy being developed to delay the onset and progression of Type 1 Diabetes (T1D) by addressing the underlying autoimmune cause. SAB's development pipeline also includes programs targeting infectious diseases, such as severe influenza and antibiotic resistance.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the appointment of a new Chief Executive Officer and changes in the company's board and management structure. There are no financial statements or detailed financial data presented, and the document is not an earnings release or annual/interim report. The primary focus is on management changes, which aligns with the category for announcements of changes in the company's board of directors or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (6054 characters) supports that it is a full report rather than a brief announcement or certification.
2024-02-02 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 26, 2024, by SAB Biotherapeutics, Inc. It announces the entry into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. The content focuses on the terms of the equity offering, the potential sale of common stock up to $20 million, and related legal exhibits. There are no financial statements or detailed financial results presented, nor is this a full annual or quarterly report. The document is an announcement of a capital raising agreement and related financing activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (6840 characters) supports it being a full filing rather than a brief announcement. Confidence is high due to the clear description of a financing agreement and absence of other report types.
2024-01-26 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of up to $20 million of common stock through a controlled equity offering sales agreement. The text includes information about the sales agent, offering terms, risk factors, use of proceeds, dilution, and plan of distribution. It is clearly a capital raising document related to financing activities, not a financial report, management discussion, or regulatory filing unrelated to financing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, not just an announcement or notice, so it is not an RPA or RNS.
2024-01-26 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce specific events or updates about the company. The text indicates that the company received a notification from Nasdaq about regaining compliance with a listing rule, which is an event update rather than a financial report or detailed filing. The document is short (3124 characters) and includes a press release as an exhibit. There is no detailed financial data, management discussion, or audit information. This fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-25 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 19, 2024, by SAB Biotherapeutics, Inc. It primarily announces the availability of an updated corporate presentation on the company's website and furnishes the presentation as Exhibit 99.1. The text explicitly states that the presentation is being made available and is incorporated by reference, but the document itself does not contain the full presentation or detailed financial data. The document is relatively short (6442 characters) and serves as a disclosure of the presentation rather than the presentation itself. According to the 'Menu vs Meal' rule, this is an announcement of a report (the presentation) rather than the report itself. Therefore, the appropriate classification is Investor Presentation (IP).
2024-01-19 English
8-K
Share Issue/Capital Change Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes a reverse stock split approved by the board and stockholders, including details of the stock split ratio, effective date, and voting results. It also references a press release and certificate of amendment as exhibits. The document is not a full financial report, earnings release, or proxy statement but rather an announcement of a corporate action and voting results. This fits the category of Share Issue/Capital Change (SHA) because it involves a reverse stock split, which is a capital structure change. The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Therefore, the correct classification is SHA with high confidence.
2024-01-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.